Skip to content

Study · Ex vivo tissue · 1986

1 result

Interaction of neuropeptides and biogenic amines on cyclic adenosine monophosphate accumulation in hypothalamic nuclei.

Redgate ES, Deupree JD, Axelrod J

Brain research1 Feb 1986Cited by 21 (Europe PMC)

PMID3004657 (opens in a new tab)DOI10.1016/0006-8993(86)90722-5 (opens in a new tab)PepBankPUB-03004657
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In micropunched hypothalamic nuclei, oxytocin stimulated cAMP accumulation selectively in one or two of the paraventricular, supraoptic and lateral hypothalamic structures.

    In plain wordsIn lab tests on brain tissue, oxytocin raised cAMP in one or two of the three hypothalamic areas tested.

    Peptide
    Oxytocin
    Outcome
    IncreasecAMP accumulation in hypothalamic nuclei
    Study

    n: not reported in source

    Micropunched hypothalamic nuclei (PVH, SON, LH)
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Bradykinin, alpha-melanocyte-stimulating (alpha-MSH), luteinizing hormone-releasing hormone (LH-RH), oxytocin and carbamylcholine stimulated cAMP accumulation selectively in one or two of the above structures.
    1 context sentence
    Summary · context
    Neuropeptides and biogenic amines known to be present in neurons or afferent terminals in the paraventricular nucleus (PVH), supraoptic nucleus (SON) and/or lateral hypothalamus (LH) were added to small areas of these structures obtained by micropuncture and cyclic adenosine monophosphate (cAMP) levels were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.